Objective: To assess clinicians’ perspectives on the role of faropenem in the management of recurrent and multidrug-resistant (MDR) bacterial infections in adults, with particular emphasis on its effectiveness, safety, and tolerability. Methods: This cross-sectional study was conducted among clinicians across India using a structured 23-item questionnaire to assess the perceived effectiveness, tolerability, and therapeutic outcomes of faropenem in recurrent and MDR bacterial infections. Responses were analyzed descriptively using frequencies and percentages, and the results were presented using Microsoft Excel. Results: Among the 91 participants, nearly 76% of clinicians identified Streptococcus pneumoniae as the most common causative organism of respiratory infections. About 47% of respondents reported occasionally encountering MDR organisms in routine practice. Broad-spectrum antimicrobial coverage was considered the most important factor influencing antibiotic selection by approximately 46% of clinicians. Around 46% of respondents also reported frequently performing culture and sensitivity testing prior to antibiotic initiation. More than half (56.04%) of the participants preferred faropenem for 5–7 days in adult infections. Nearly 48% preferred faropenem in 11–25% of patients with urinary tract infections (UTIs), while about 46% recommended it in 11–25% of patients with skin and soft tissue infections (SSTIs). Additionally, around 41% of clinicians reported regularly monitoring patients for adverse effects or complications during faropenem therapy. Conclusion: The survey findings indicate that faropenem is widely used in the management of adult bacterial infections, particularly UTIs and SSTIs. Broad-spectrum antimicrobial coverage and culture-based decision-making strongly influence antibiotic selection, while Streptococcus pneumoniae remains the predominant respiratory pathogen.